Mast Therapeutics, Inc.

Industry

  • Pharmaceuticals
    • Drug Delivery
      • Pulmonary
    • Vaccines
  • Biotechnology

Other Names/Subsidiaries

  • Adventrx Pharmaceuticals, Inc.
  • Aires Pharmaceuticals, Inc.
  • SynthRx, Inc.
  • Aires Pharmaceuticals
See more in Biomedtracker

Latest on Mast Therapeutics, Inc.

Scrip

In Hindsight, Savara Wishes It Led With Patient-Reported Secondary Endpoint For Molgradex

 
• By Joseph Haas

It’s fairly standard for a biotech to frame a study that missed its primary endpoint as offering promise on other measures, but Savara Inc. ’s attempt to depict its unsuccessful Phase III IMPALA stud

Scrip

Finance Watch: Summer Heat Extends To Biopharma IPOs With Nine In July, 45 This Year

 
• By Mandy Jackson

With 45 biopharmaceutical company initial public offerings in the US this year through the end of July, including nine IPOs that month, 2018 has already surpassed 2017, when 42 drug developers went pu

Scrip

Appointments: Five Prime, Depomed, Gilead, Arix Bioscience and Corbus

 
• By Lubna Ahmed

Five Prime Therapeutics Inc. , a company focused on immuno-oncology therapeutics, has appointed its chief operating officer (COO) Aron Knickerbocker as CEO and president – effective Jan. 1, 2017.

Scrip

Antibiotic Pipeline Profile: Targeting Delivery To Infection Site

 
• By Bridget Silverman

Several antibiotic drug developers are looking to alternative delivery systems to offer localized delivery for anti-infective agents – such as inhaled formulations that target the lungs – a pathway th